Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074059 · ClinicalTrials.gov registry record · Phase 2
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02074059 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 80 participants.
The verdict
NCT02074059, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to neonates receiving nCPAP alone.
Interventions
- DRUG Lucinactant for Inhalation
- DEVICE nCPAP alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074059
The ClinicalTrials.gov registry entry for NCT02074059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lucinactant for Inhalation is the first listed.
NCT02074059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074059 about?
NCT02074059 is a clinical study titled "Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates". The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks gestational age who are receiving nasal continuous positive airway pressure (...
What is the current status of trial NCT02074059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02074059?
The interventions under investigation include: Lucinactant for Inhalation (DRUG), nCPAP alone (DEVICE).
Who is sponsoring clinical trial NCT02074059?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.